Institut Català de la Salut
[de la Fuente A] Group for Biomedical Research in Respiratory Infection & Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain. Group for Biomedical Research in Respiratory Infection & Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain. [López-Sánchez J] Department of General and Gastrointestinal Surgery, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL) and Universidad de Salamanca, Salamanca, Spain. [Vaquero-Roncero LM, Sánchez Barrado ME] Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES, CB22/06/00035), Instituto de Salud Carlos III, Madrid, Spain. Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. [Merino García M] Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de León, León, Spain. [Sánchez-Hernández MV] Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. [Chiscano-Camón L, Ferrer R, Ruiz-Rodríguez JC] Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Shock, Disfunció Orgànica i Ressuscitació, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [González-López JJ] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-07-09T12:15:53Z
2024-07-09T12:15:53Z
2024-06-18
Biomarkers; Infection; Synergy
Biomarcadors; Infecció; Sinergia
Biomarcadores; Infección; Sinergia
Objectives Identifying host response biomarkers implicated in the emergence of organ failure during infection is key to improving the early detection of this complication. Methods Twenty biomarkers of innate immunity, T-cell response, endothelial dysfunction, coagulation, and immunosuppression were profiled in 180 surgical patients with infections of diverse severity (IDS) and 53 with no infection (nIDS). Those better differentiating IDS/nIDS in the area under the curve were combined to test their association with the sequential organ failure assessment score by linear regression analysis in IDS. Results were validated in another IDS cohort of 174 patients. Results C-reactive protein, procalcitonin, pentraxin-3, lipocalin-2 (LCN2), tumoral necrosis factor-α, angiopoietin-2, triggering receptor expressed on myeloid cells-1 (TREM-1) and interleukin (IL)-15 yielded an area under the curve ≥0.75 to differentiate IDS from nIDS. The combination of LCN2, IL-15, TREM-1, angiopoietin-2 (Dys-4) showed the strongest association with sequential organ failure assessment score in IDS (adjusted regression coefficient; standard error; P): Dys-4 (3.55;0.44; <0.001), LCN2 (2.24; 0.28; <0.001), angiopoietin-2 (1.92; 0.33; <0.001), IL-15 (1.78; 0.40; <0.001), TREM-1(1.74; 0.46; <0.001), tumoral necrosis factor-α (1.60; 0.31; <0.001), pentraxin-3 (1.12; 0.18; <0.001), procalcitonin (0.85; 0.12; <0.001). Dys-4 provided similar results in the validation cohort. Conclusions There is a synergistic impact of innate immunity hyper-activation (LCN2, IL-15, TREM-1) and endothelial dysfunction (angiopoietin-2) on the magnitude of organ failure during infection.
This work was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund/European Social Fund “A way to make Europe“/”Investing in your future” [Project “PI19/00590” (JFBM), Project “PI22/00968” (JFBM), Sara Borrell program “CD018/0123” (APT) and PFIS program “FI20/00278” (AdlF)]. The funding sources did not play any role in the design of the study and collection, analysis, interpretation of data, or writing the manuscript.
Article
Published version
English
Septicèmia - Diagnòstic; Marcadors bioquímics; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; DISEASES::Bacterial Infections and Mycoses::Infection::Sepsis; DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Shock::Multiple Organ Failure; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores; ENFERMEDADES::infecciones bacterianas y micosis::infección::sepsis; ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::choque::insuficiencia multiorgánica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz
Elsevier
International Journal of Infectious Diseases;146
https://doi.org/10.1016/j.ijid.2024.107142
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]